Mayne Pharma poised to enter world’s largest pharmaceutical market
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Mayne Pharma Group Limited (ASX:MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) announced on Thursday morning that the former has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for E4/DRSP, a combined oral contraceptive indicated for the prevention of pregnancy.
Two phase 3 clinical studies of E4/DRSP including more than 4400 women from various global regions have demonstrated very positive outcomes for efficacy and safety in a product that has achieved a desirable bleeding profile and excellent tolerability.
If approved by the FDA, E4/DRSP is expected to be made available to patients in the US market in the first half of calendar 2021.
Given US sales of combined hormonal contraceptives are more than US$4 billion per annum, there is the potential for this drug to generate substantial revenues for Mayne Pharma.
E4/DRSP is a novel, next generation oral contraceptive containing Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg.
E4 is a naturally occurring estrogen that is produced by the human foetal liver during pregnancy.
Targeting 2021 launch
Following more than 20 years of research and development, Mayne Pharma’s development and manufacturing partner Mithra can synthesise E4 at scale through a complex plant-based production process.
Commenting on this development, Mayne Pharma chief executive Scott Richards said, “The NDA filing is a major milestone for Mayne Pharma and our development partner Mithra Pharmaceuticals.
‘’We are now one step closer to making this new oral contraceptive that we believe to be safe, effective and well-tolerated available to American women.
‘’We confirm our earlier stated goal of bringing this product to market in the first half of calendar 2021.”
Should the group meet this target, it will be well-placed to achieve the sharp uptick in earnings per share that are forecast to occur in fiscal 2022.
Consensus forecasts currently indicate that earnings per share will increase from 1.9 cents in fiscal 2021 to 5.6 cents in 2022, with the latter implying a seemingly conservative forward PE multiple of just over six relative to Wednesday’s closing price of 34.5 cents.
With COVID-19 having a significant impact on retail sales in the US, investors are likely to be looking to identify companies that generate income from non-discretionary areas such as contraception.
This may account for the substantial rebound of about 70% in Mayne Pharma’s share price since it bottomed out at 19.5 cents on 19 March.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
